These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 12704813)

  • 41. CSF biomarkers predict rate of cognitive decline in Alzheimer disease.
    Kester MI; van der Vlies AE; Blankenstein MA; Pijnenburg YA; van Elk EJ; Scheltens P; van der Flier WM
    Neurology; 2009 Oct; 73(17):1353-8. PubMed ID: 19858456
    [TBL] [Abstract][Full Text] [Related]  

  • 42. CSF and MRI markers independently contribute to the diagnosis of Alzheimer's disease.
    Schoonenboom NS; van der Flier WM; Blankenstein MA; Bouwman FH; Van Kamp GJ; Barkhof F; Scheltens P
    Neurobiol Aging; 2008 May; 29(5):669-75. PubMed ID: 17208336
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Episodic memory and speed/attention deficits are associated with Alzheimer-typical CSF abnormalities in MCI.
    Nordlund A; Rolstad S; Klang O; Lind K; Pedersen M; Blennow K; Edman A; Hansen S; Wallin A
    J Int Neuropsychol Soc; 2008 Jul; 14(4):582-90. PubMed ID: 18577287
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Are the CSF levels of 24S-hydroxycholesterol a sensitive biomarker for mild cognitive impairment?
    Leoni V; Shafaati M; Salomon A; Kivipelto M; Björkhem I; Wahlund LO
    Neurosci Lett; 2006 Apr 10-17; 397(1-2):83-7. PubMed ID: 16406316
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Longitudinal CSF and MRI biomarkers improve the diagnosis of mild cognitive impairment.
    de Leon MJ; DeSanti S; Zinkowski R; Mehta PD; Pratico D; Segal S; Rusinek H; Li J; Tsui W; Saint Louis LA; Clark CM; Tarshish C; Li Y; Lair L; Javier E; Rich K; Lesbre P; Mosconi L; Reisberg B; Sadowski M; DeBernadis JF; Kerkman DJ; Hampel H; Wahlund LO; Davies P
    Neurobiol Aging; 2006 Mar; 27(3):394-401. PubMed ID: 16125823
    [TBL] [Abstract][Full Text] [Related]  

  • 46. CSF beta-amyloid 1-42 and tau in Tunisian patients with Alzheimer's disease: the effect of APOE epsilon4 allele.
    Smach MA; Charfeddine B; Lammouchi T; Harrabi I; Ben Othman L; Dridi H; Bennamou S; Limem K
    Neurosci Lett; 2008 Aug; 440(2):145-9. PubMed ID: 18555606
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Biochemical markers for Alzheimer disease].
    Czarna JM; Waldemar G; Heegaard NH
    Ugeskr Laeger; 2006 Mar; 168(10):1010-4. PubMed ID: 16522291
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The apolipoprotein E ε4 allele plays pathological roles in AD through high protein expression and interaction with butyrylcholinesterase.
    Darreh-Shori T; Modiri N; Blennow K; Baza S; Kamil C; Ahmed H; Andreasen N; Nordberg A
    Neurobiol Aging; 2011 Jul; 32(7):1236-48. PubMed ID: 19713000
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [The measurement of phosphorylated tau in human cerebrospinal fluid as a diagnostic marker for Alzheimer's disease].
    Urakami K; Ito N; Arai H; Ishiguro K; Ohno H; Nakashima K
    Seishin Shinkeigaku Zasshi; 2003; 105(4):393-7. PubMed ID: 12806900
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Beta-site amyloid precursor protein cleaving enzyme 1 (BACE1) as a biological candidate marker of Alzheimer's disease.
    Hampel H; Shen Y
    Scand J Clin Lab Invest; 2009; 69(1):8-12. PubMed ID: 18609117
    [TBL] [Abstract][Full Text] [Related]  

  • 51. ApoE alleles and tau markers in patients with different levels of cognitive impairment.
    Lavados M; Farías G; Rothhammer F; Guillon M; Mujica MC; Maccioni C; Maccioni RB
    Arch Med Res; 2005; 36(5):474-9. PubMed ID: 16099324
    [TBL] [Abstract][Full Text] [Related]  

  • 52. CSF biomarkers for mild cognitive impairment.
    Blennow K
    J Intern Med; 2004 Sep; 256(3):224-34. PubMed ID: 15324365
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cerebrospinal fluid tau, A beta, and phosphorylated tau protein for the diagnosis of Alzheimer's disease.
    Formichi P; Battisti C; Radi E; Federico A
    J Cell Physiol; 2006 Jul; 208(1):39-46. PubMed ID: 16447254
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Oligomerization partially explains the lowering of Abeta42 in Alzheimer's disease cerebrospinal fluid.
    Englund H; Degerman Gunnarsson M; Brundin RM; Hedlund M; Kilander L; Lannfelt L; Pettersson FE
    Neurodegener Dis; 2009; 6(4):139-47. PubMed ID: 19521063
    [TBL] [Abstract][Full Text] [Related]  

  • 55. CSF phosphorylated tau protein and mild cognitive impairment: a prospective study.
    Arai H; Ishiguro K; Ohno H; Moriyama M; Itoh N; Okamura N; Matsui T; Morikawa Y; Horikawa E; Kohno H; Sasaki H; Imahori K
    Exp Neurol; 2000 Nov; 166(1):201-3. PubMed ID: 11031097
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Longitudinal changes of CSF biomarkers in memory clinic patients.
    Bouwman FH; van der Flier WM; Schoonenboom NS; van Elk EJ; Kok A; Rijmen F; Blankenstein MA; Scheltens P
    Neurology; 2007 Sep; 69(10):1006-11. PubMed ID: 17785669
    [TBL] [Abstract][Full Text] [Related]  

  • 57. CSF biomarkers for mild cognitive impairment and early Alzheimer's disease.
    Andreasen N; Blennow K
    Clin Neurol Neurosurg; 2005 Apr; 107(3):165-73. PubMed ID: 15823670
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Improved discrimination of autopsy-confirmed Alzheimer's disease (AD) from non-AD dementias using CSF P-tau(181P).
    Koopman K; Le Bastard N; Martin JJ; Nagels G; De Deyn PP; Engelborghs S
    Neurochem Int; 2009 Sep; 55(4):214-8. PubMed ID: 19524111
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Association between butyrylcholinesterase and cerebrospinal fluid biomarkers in Alzheimer's disease patients.
    Gabriel AJ; Almeida MR; Ribeiro MH; Durães J; Tábuas-Pereira M; Pinheiro AC; Pascoal R; Santana I; Baldeiras I
    Neurosci Lett; 2017 Feb; 641():101-106. PubMed ID: 28108398
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Basic and clinical studies on the measurement of tau protein in cerebrospinal fluid as a biological marker for Alzheimer's disease and related disorders: multicenter study in Japan.
    Nishimura T; Takeda M; Nakamura Y; Yosbida Y; Arai H; Sasaki H; Shouji M; Hirai S; Khise K; Tanaka K; Hamamoto M; Yamamoto H; Matsubayashi T; Urakami K; Adachi Y; Nakashima K; Toji H; Nakamura S; Yoshida H
    Methods Find Exp Clin Pharmacol; 1998 Apr; 20(3):227-35. PubMed ID: 9646285
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.